Altimmune (ALT) Gains from Investment Securities (2018 - 2022)
Altimmune (ALT) posted quarterly Gains from Investment Securities of -$1.8 million for Q1 2022, down 302.27% year-over-year from $880000.0 in Q1 2021, and down 106.98% quarter-over-quarter from -$860000.0 in Q4 2021.
Powered by 
Analysis
Altimmune (ALT) Gains from Investment Securities (2018 - 2022) Analysis & Trends
Altimmune (ALT) has reported Gains from Investment Securities for 5 consecutive years, with -$1.8 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Gains from Investment Securities fell 302.27% year-over-year to -$1.8 million; the TTM figure through Dec 2022 stood at -$2.6 million (down 477.14% YoY), while the FY2022 annual figure was $86000.0, down 87.71% from the prior year.
- Gains from Investment Securities fell to -$1.8 million in Q1 2022 per ALT's latest filing, from -$860000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $11.9 million in Q2 2020 and bottomed at -$1.8 million in Q1 2022.
- Historically, Gains from Investment Securities has averaged $2.1 million across 5 years, with a median of $442000.0 in 2018.
- Annual changes were most pronounced in 2020 — Gains from Investment Securities soared 11547.37% — and 2022, when it tumbled 302.27%.
- Altimmune's Gains from Investment Securities stood at $4000.0 in 2018, then sank by 2000.0% to -$76000.0 in 2019, then soared by 7205.26% to $5.4 million in 2020, then plunged by 115.93% to -$860000.0 in 2021, then tumbled by 106.98% to -$1.8 million in 2022.
- Business Quant data shows ALT's Gains from Investment Securities at -$1.8 million in Q1 2022, -$860000.0 in Q4 2021, and $1.7 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | -1.80 Mn |
| Dec 31, 2021 | -860,000.00 |
| Sep 30, 2021 | 1.68 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | 880,000.00 |
| Dec 31, 2020 | 5.40 Mn |
| Sep 30, 2020 | 8.70 Mn |
| Jun 30, 2020 | 11.90 Mn |
| Mar 31, 2020 | 1.75 Mn |
| Sep 30, 2019 | -76,000.00 |
| Dec 31, 2018 | 4,000.00 |
| Sep 30, 2018 | -806,225.00 |
| Jun 30, 2018 | 5.23 Mn |
| Mar 31, 2018 | -1.55 Mn |